Leukemia severe thrombopenia at that time. After discontinuation of As 2 O 3 the clinical signs of pseudotumor cerebri diappeared within 3 weeks. A bone marrow examination performed at the end of March 1999 (13 days after discontinuation of As 2 O 3 ) showed a complete remission of APL. The skin nodules had also regressed and could only be recognized as faint hyperpigmentations. Examination of the spinal fluid at that time showed no pathological result. The patient remained off therapy and recovered completely until May 1999, when there was still no evidence for relapse. The patient then successfully underwent HLA-identical allogeneic bone marrow transplantation.
Because of limited experience with As 2 O 3 treatment the spectrum of acute and chronic side-effects still remains to be completely defined. 4 The most frequent acute adverse effects of treatment of APL with As 2 O 3 reported so far seem to be fluid retention, cardiac and hepatic toxicity as well as gastrointestinal and dermatological symptoms. Polyneuropathy and muscular atrophy were noted as chronic side-effects. 1, 4 PTC is defined as a clinical pattern characterized by a syndrome of intracranial hypertension without signs of an intracranial spaceoccupying lesion or of an infectious process. 5 Our patient complained about abdominal discomfort during the first days of treatment and a mild elevation of alkaline phosphatase was noted. There was no further evidence of acute As 2 O 3 toxicity until the symptoms of elevated intracranial pressure occurred.
Several cases of PTC after differentiation therapy with ATRA for APL have been described in the literature, especially occurring in pediatric patients and associated with hyperleukocytosis. Vasogenic cerebral edema induced by the disruption of the integrity of the blood-brain barrier may possibly account for the iatrogenic type of PTC. 5 A further possible mechanism might be increased production of cerebrospinal fluid through disturbance of the Na+/K+ adenosine triphosphatase pump or modulation of the intracellular levels of cyclic adenosine monophosphate in the arachnoid villi. The exact pathogenesis, however, still remains to be established. After drug withdrawal the symptoms usually regress rapidly.
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Our patient is an adult and occurrence of PTC was not associated with leukocytosis. Since there were no signs of any central nervous system abnormality and symptoms regressed upon drug withdrawal, it seems likely that PTC was caused by As 2 O 3 . ATRA was given to our patient twice previously for an overall duration of about 6 months, and during those periods there occurred no neurological symptoms.
To our knowledge, this is the first report of a case of PTC associated with treatment of APL with As 2 O 3 . Although PTC is a rare complication in adult APL, it is important to differentiate it from cerebral hemorrhage and one has to be aware that PTC may not only occur after differentiation therapy with ATRA but also after salvage treatment with As 2 O 3 .
Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele TO 
THE EDITOR
The myelodysplastic syndromes (MDS) are clonal disorders originating from a pluripotent stem cell. Cytopenia is frequently observed in such patients. Because of the similarities between aplastic anemia (AA) and hypoplastic MDS, immunosuppressive therapies such as high-dose methylprednisolone, antithymocyte globulin (ATG), and cyclosporine (CyA), have also used to treat cytopenia of hypoplastic MDS, with response seen in two of five patients, 1 likewise throughout 11 of 25 patients (44%), 2 and 14 of 17 patitents (82%), 3 respectively. Nakao et al 4 reported that in the treatment of CyA for AA patients, the response rate to CyA in patients with DRB1*1501 (92%) was significantly higher than that in patients with DRB1*1502 (41%) and in patients with other DR alleles (57%). Therefore, we treated MDS patients with CyA to see whether the effectiveness of CyA treatment for MDS is associated with a patient's HLA-DRB1*1501 allele.
We treated nine patients with refractory anemia (RA) and one with RA with excess blasts (RAEB) with CyA. These patients were not responsive to conventional therapy, that is, anabolic steroid, corticosteroid, erythropoietin or granulocyte colony-stimulating factor ther- apy. The patients were diagnosed as having RA or RAEB according to FAB criteria, and chromosomal analysis was performed in all patients. CyA (50-300 mg/day) was administered to patients in whom anabolic steroids and small doses of prednisolone were usually used for a long time. However, those drugs and their doses were not changed before or after CyA treatment. Since aged patients tended to have side-effects of CyA, we started to treat patients with a low-dose CyA, 50 mg/day. Then, the treatment dose of CyA was increased to 200 or 300 mg/day, stepwise. Response criteria were defined as a resolution of all transfusion requirements and a у2 g/dl increase in hemoglobin as compared with pretreatment levels. DNA was extracted from leukocytes in peripheral blood to determine a genotype of HLA-DRB1. DRB1 alleles were amplified using polymerase chain reaction and typed using the restriction fragment-length polymorphism method, which was performed by Shionogi Biomedical Laboratory (Osaka, Japan).
The results of CyA therapy in 10 MDS patients were that six patients (60%) responded to CyA well, as shown in Table 1 . Three of them did not require a regular transfusion of red blood cells (RBC) (one unit every 2 weeks). The other three patients still needed blood transfusions of RBC, but the requirement of transfusion was reduced from one unit every 2 weeks to one every 1 month. The remaining four patients did not show any improvement of requirement in RBC transfusions or in other clinical data. The platelet count increased from 4 to 34 × 10 3 /l in patient No. 3 (Table 1) following CyA treatment. However, the other good responders did not show obvious improvement in platelet counts. The analysis of HLA-DRB1 type showed that five of 10 Japanese patients had a haplotype of HLA-DRB1*1501 and one patient had a homotype of it. All patients who had the HLA-DRB1*1501 required no or fewer RBC transfusions within 1-2 months after CyA treatment. On the other hand, four patients who had DRB1 types other than 1501 required the RBC transfusion consistently. Our data clearly indicated that the presence of the HLA-DRB1*1501 allele predicts a good response to CyA therapy.
Nakao et al 4 reported that AA patients with HLA-DRB1*1501 were dependent on CyA therapy and tended to develop pancytopenia after Leukemia dose reduction or cessation of CyA. Because CyA was not reduced in our patients, we do not know whether the good responders were dependent on CyA or not. The time from the beginning of CyA treatment to the first hematologic effect was 1-2 months (median, 1) in this study, while it was 1-9 months (median, 2) in Jonasova's study, 3 suggesting that MDS patients with HLA-DRB1*1501 tend to respond to CyA more quickly.
The frequency for the HLA-DRB1*1501 allele was 6.1% in the general Japanese population, 5 whereas six of 10 MDS patients (60%) had this allele in the present study. There was a long time between diagnosis and CyA treatment in our patients, which ranged from 10 to 144 months (median, 76), and their diseases were refractory to conventional therapy for MDS. Although the reason for the high frequency of HLA-DRB1*1501 was unknown in this study, the HLA-DRB1*1501 allele might be more frequently found in MDS patients refractory to conventional therapy.
Our results suggested that the presence of the HLA-DRB1*1501 genotype is a favorable factor in predicting a good response to CyA therapy for MDS. One needs a good number of patients treated with CyA and a long follow-up period to clarify the relation of HLA genotype to clinical effects of CyA.
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